Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
licensing
Pharma
Novartis returns PD-1 to BeiGene in another cancer drug divorce
Novartis has ended its major cancer immunotherapy collaboration with BeiGene years after touting the benefits of having a PD-1 inhibitor.
Angus Liu
Sep 19, 2023 9:10am
Otsuka, Astellas, Exelixis and Insilico—Fierce Pharma Asia
Sep 15, 2023 9:00am
Arbitration win over J&J gives Alkermes a $425M boost
Jun 6, 2023 3:23pm
Neurocrine gives up on Parkinson's drug Ongentys
May 3, 2023 10:55am
After splashing $1B, Roche returns Gavreto to Blueprint
Feb 23, 2023 11:29am
Biogen bets $10M on implant to improve delivery of Spinraza
Jan 10, 2023 7:25am